Sun Pharma declines nearly 3% as Halol facility gets 8 US FDA observations

The company said it was preparing the response to the observations, which will be submitted to the US FDA within 15 business days

Shares of Sun Pharma cracked as much as 2.84 per cent to Rs 426.50 apiece on the BSE on Monday after the company informed that the US FDA has issued a Form 483, with eight observations for its Halol (Gujarat) facility. The inspection was conducted from December 03-13, 2019, the company said in its regulatory filing. 

At 09:30 am, the stock was trading over 1.50 per cent lower at Rs 431.70. In comparison, the benchmark S&P BSE Sensex was trading 72 points or 0.18 per cent higher at 41,082 levels.

Sun Pharma further said it was preparing the response to